Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mateo Boberg1, Bjørn Ebdrup1, Poul Videbech1

  • 1Psykiatrisk Center Glostrup.

Ugeskrift for Laeger
|October 18, 2022
PubMed
Summary
This summary is machine-generated.

Attention deficit hyperactivity disorder (ADHD) symptoms are prevalent in schizophrenia, complicating treatment due to opposing medication effects. Central stimulant drugs may help some patients, but require specialist supervision and caution due to limited evidence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodological limitations of anxiety screening tools used in migraine studies -a narrative review.

Cephalalgia : an international journal of headache·2026
Same author

Acute SARS-CoV-2 infection and self-reported post-acute cognitive dysfunctions from the Danish EFTER-COVID survey.

Communications medicine·2026
Same author

Feasibility of a Supportive Cancer Care Intervention for Patients With Pre-Existing Severe Mental Disorders-The CASEMED Model.

Psycho-oncology·2026
Same author

Quality in specialist palliative care for patients with pre-existing severe mental disorders: A retrospective cohort study.

Palliative medicine·2026
Same author

Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.

Molecular psychiatry·2026
Same author

Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study.

BJPsych open·2025
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Attention deficit hyperactivity disorder (ADHD) symptoms frequently co-occur with schizophrenia.
  • Cognitive impairments, including attention deficits, are common in schizophrenia patients.
  • Treating comorbid ADHD symptoms in schizophrenia is challenging due to conflicting pharmacological actions.

Purpose of the Study:

  • To review the potential benefits and risks of using central stimulant drugs for ADHD symptoms in schizophrenia.
  • To highlight the need for specialist management and caution in such treatment approaches.

Main Methods:

  • This study is a review of existing literature.
  • It synthesizes information on the interaction between ADHD medications and antipsychotics.

Related Experiment Videos

  • It discusses the potential efficacy and safety of central stimulants in schizophrenia.

    • Main Results:

    • ADHD medications and antipsychotics have opposing effects on dopamine levels.
    • Central stimulant drugs might offer benefits for specific schizophrenia patients with ADHD symptoms.
    • There is insufficient evidence to establish clinical guidelines for this treatment.

    Conclusions:

    • Treatment with central stimulants for ADHD symptoms in schizophrenia should be conducted by specialists.
    • Inpatient specialist supervision and extreme caution are recommended.
    • Further research is needed to develop evidence-based clinical guidelines.